XOMA Corporation (XOMA) News
Filter XOMA News Items
XOMA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XOMA News Highlights
- XOMA's 30 day story count now stands at 2.
- Over the past 27 days, the trend for XOMA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest XOMA News From Around the Web
Below are the latest news stories about XOMA Corp that investors may wish to consider to help them evaluate XOMA as an investment opportunity.
XOMA to Present at Aegis Capital Corp Investor ConferenceEMERYVILLE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chief Executive Officer, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET. The conference will be held from February 23-25, 2022, from 8:30 AM until 5:30 PM ET daily, and can be viewed at https://bit.ly/3BoscU |
XOMA's (NASDAQ:XOMA) investors will be pleased with their massive 368% return over the last five yearsWhile XOMA Corporation ( NASDAQ:XOMA ) shareholders are probably generally happy, the stock hasn't had particularly... |
XOMA Declares Quarterly Preferred Stock DividendsEMERYVILLE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (XOMA or the Company) today announced its Board of Directors has authorized the following cash dividends to holders of XOMAs Series A and Series B Cumulative Preferred Stock: |
XOMA to Present at Upcoming Investor ConferencesEMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences: Biotech Showcase 2022 held virtually January 10-12 and January 17-19, 2022. Mr. Neal will hold a fireside chat titled, “Royalty Licenses: An Economic Asset Often Ignore |
XOMA Announces Evolution of Company Leadership and Succession PlanningChief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director |
XOMA Co. (NASDAQ:XOMA) Stock Position Raised by State Street CorpState Street Corp lifted its stake in XOMA Co. (NASDAQ:XOMA) by 13.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 120,424 shares of the biotechnology companys stock after acquiring an additional 14,475 shares during the period. State Street Corp owned 1.06% of XOMA worth $4,094,000 [] |
Botulinum Market Expansion Projected to Gain an Uptick During 2021-2027 Covid-19 Analysis | XOMA, AlphaVaxAnother exploration Titled "Worldwide Botulinum 2019-Market Research Report" gives the Professional and inside and out assessment of extent of momentum and future market and survey of Product Specification, showcase pattern , item type and creation investigation considering central point, for |
Should Weakness in XOMA Corporation's (NASDAQ:XOMA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 22% over the past three months, it is easy to disregard XOMA (NASDAQ:XOMA). However, the company's... |
10 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value FundIn this article, we discuss the 10 best biotech stocks to buy according to Mark Lampert. You can skip our detailed analysis of Lampert’s Biotechnology Value Fund, and go directly to the 5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark Lampert is an American investor who founded BVF Partners Ltd. […] |
XOMA (NASDAQ:XOMA) Upgraded by Zacks Investment Research to HoldZacks Investment Research upgraded shares of XOMA (NASDAQ:XOMA) from a strong sell rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports. According to Zacks, XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological [] |